Novo Nordisk plans to invest more than EUR 100 million ($113 million) in production facilities at its site in Chartres, France. The new facilities will be built on Novo Nordisk’s existing 31,000-square meter site in Chartres, which produces a range of the company’s insulin products as well as FlexPen, an insulin injection device.

Novo Nordisk has invested EUR 300 million ($338 million) in France over the past 15 years and today employs 1,100 employees at the site. The planned expansion is estimated to create around 250 new jobs once the facilities are fully operational within three to four years.

In addition to the 1,100 employees in Chartres, Novo Nordisk employs 300 people in its affiliate in Paris, which is responsible for the company’s medical, regulatory and commercial activities in France.

Source: Novo Nordisk